Weekly Rundown: BMS teams up with Anthropic to power drug discovery with AI FDA approvals, pharma deals, and more led the news this week. Written byDDN editorial team

https://www.drugdiscoverynews.com/weekly-rundown-bms-teams-up-with-anthropic-to-power-drug-discovery-with-ai-17181?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9u6i-HRDk14t_vYIC8sQ2nORNlU8CSMtIjg-pkae46fBL4R-7pLQRUGGLOUrVfkKevRNJzpF0QgqHFMKyJmMZhVVATqQ&_hsmi=420013337&utm_content=420013337&utm_source=hs_email In a move that will scale AI to more than 30,000 employees, Bristol Myers Squibb (BMS) announced a partnership with Anthropic to deploy its AI platform Claude across its research, clinical development, manufacturing, commercial, and corporate functions. The company described the collaboration as a “meaningful evolution in how BMS deploys AI, moving beyond conversational tools that have defined the first wave of enterprise adoption, toward agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations.” BMS outlined three main priorities in the statement, including using Claude Code to accelerate engineering, embedding AI agents into existing drug discovery, development, manufacturing and commercial workflows, and integrating Claude into BMS’ “institutional knowledge.” Eric Kauderer-Abrams, Head of Life Sciences at Anthropic, said in the press release, “By giving employees access to Claude’s agentic capabilities — connected to thousands of data sources across the company — BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time.” – Allison Whitten